02/11/04 -- Lipid Sciences, Inc. (Nasdaq: LIPD) announced that a poster exhibited at the 11th Conference on Retroviruses and Opportunistic Infections in San Francisco illustrates that a delipidated retrovirus (SIV-Mac251) can elicit a broader and more robust cellular immune response than live virus at a much lower dose than is typically used for preventive vaccines. This supports the premise that delipidating HIV has the potential to be used as the basis for a novel approach to the development of an autologous therapeutic vaccine for HIV-infected patients.

The poster exhibit, entitled "Use of Delipidated SIV to Augment SIV-Specific CD4+ and CD8+ T Cell Memory Responses in Mice -- A Model for a New Therapeutic Vaccination Strategy Against HIV Infection," was presented on February 10, 2004 by Dr. James E.K. Hildreth, Professor of Pharmacology and Molecular Sciences, and of Pathology at Johns Hopkins School of Medicine. The study was conducted under the direction of Dr. Aftab A. Ansari, Professor, Department of Pathology and Laboratory Medicine, Emory University. Drs. Hildreth and Ansari are members of Lipid Sciences, Inc.'s Viral Advisory Board.

The Conference on Retroviruses and Opportunistic Infections is a gathering of the world's leading researchers who are seeking to understand, prevent, and treat HIV/AIDS and its complications. This conference provides a forum for translating laboratory and clinical research into medical applications.

Dr. S. Lewis Meyer, President and CEO of Lipid Sciences, commented, "The fact that our data was accepted for presentation at such a prestigious conference is tangible evidence of the progress of our viral program. Our goal is to develop an autologous therapeutic vaccine approach for use against HIV. For Lipid Sciences this application is critical because, according to UNAIDS, there are currently 40 million people who are HIV positive, and 5 million people who become HIV-positive each year on a world-wide basis." Dr. Meyer also commented, "The broad and more robust cellular immune response achieved by this study in mice was the impetus for us to launch a series of non-human primate studies as further validation of our Viral Immunotherapy Platform. The results of these studies will bring us one step closer to presenting data to the FDA to discuss what additional steps must be completed before moving into a human clinical trial."

Lipid Sciences is engaged in the research and development of products and processes to treat major medical indications through its unique patented technology of lipid removal known as delipidation. The Company's research and development efforts are focused on potential applications for delipidation in two main areas. The Viral Immunotherapy Platform is focused on the removal of lipid coatings from viruses and other lipid-containing infectious agents by applications of our delipidation technology. It is believed that removing the agent's protective lipid coating exposes new or additional viral proteins to stimulate the body's immune system and elicit an enhanced therapeutic response to the infectious agent. This viral delipidation approach provides a novel strategy for HIV-infected patients that fills a need to provide a therapy that could be used in conjunction with current chemotherapeutic regimens. Conditions that can potentially be impacted by this technology include: HIV, Hepatitis B and Hepatitis C, West Nile and SARS.

On a parallel path, Lipid Sciences is aggressively developing its HDL Therapy Platform and significant developmental milestones have been, and we anticipate will continue to be met. This platform has the potential to become an important component in a coronary artery disease treatment regimen that integrates both acute (HDL) and long-term chronic (statin) therapies. These research and development efforts are aimed at providing potential treatments for the reversal of atherosclerosis, a disease of blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. If left untreated, these plaques are highly vulnerable to rupture and to blood clot formation which can result in a fatal myocardial infarction (heart attack). Based on recent positive in vitro results from the Company's HDL Therapy development program, the Company believes that this proprietary, practical and cost-effective delipidation process has the ability to boost HDL efficiency in reverse cholesterol transport and turn back the "cardiovascular clock" by reversing the build-up of fatty plaque in coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's HDL technology is based on a patented process that selectively and rapidly removes lipids from lipoproteins, such as HDL, without harming the proteins that carry the lipid particles.

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes to treat major medical indications in which lipids, or fats, play a key role. The Company's technologies are based on a unique patented process, known as delipidation, which selectively removes lipids from proteins. The Company's Viral Immunotherapy Platform is focused on the removal of lipid coatings from viruses and other lipid-containing infectious agents by applications of its delipidation technology. It is believed that removing the agent's protective lipid coating exposes otherwise hidden viral proteins to stimulate the body's immune system and elicit an enhanced therapeutic response to the infectious agent. Conditions that can potentially be impacted by this technology include HIV, Hepatitis B and Hepatitis C, West Nile and SARS. The Company's HDL Therapy Platform is aimed at developing potential treatments for the reversal of atherosclerosis, a disease of blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. If left untreated, these plaques are highly vulnerable to rupture and to blood clot formation which can result in a fatal myocardial infarction (heart attack). Regression of such plaques may have a major impact on reducing the risk of acute coronary events.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds or attract strategic partners or to effect other transactions; our technology not proving to be safe or effective; our inability to obtain regulatory approval for our technology, which is only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International; our reliance on collaborations with strategic partners; competition in our industry; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; product liability claims; an economic downturn in the real estate market; our dependence on key personnel; additional shares of common stock becoming available for sale following the expiration of lock-up periods; and dilution of existing stockholders' ownership due to shares of common stock having been issued to former NZ Corporation shareholders who have perfected certain rights.

The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are also available on our website: www.lipidsciences.com. If you would like to receive our press releases via email, please contact: info@lipidsciences.com.

Source: Lipid Sciences, Inc.